Department of Clinical Microbiology, Christian Medical College, Vellore, 632004, India.
Department of Medicine, Christian Medical College, Vellore, India.
Eur J Clin Microbiol Infect Dis. 2024 Dec;43(12):2453-2457. doi: 10.1007/s10096-024-04932-6. Epub 2024 Sep 19.
Stenotrophomonas maltophilia is challenging to treat due to the presence of multiple intrinsic and acquired resistance mechanisms. TMP-SMZ is the standard care of therapy for treating S. maltophilia infections; levofloxavin and minocycline are the preferred potential alternatives. Recently, in 2024, CLSI has lowered the susceptibility breakpoints for minocycline against S. maltophilia. Applying the revised minocycline's susceptibility breakpoint of ≤ 1 mg/L, susceptibility to minocycline dropped significantly from 77% (previous breakpoint, ≤ 4 mg/L) to 35% (revised breakpoint of ≤ 1 mg/L). In the wake of this change, minocycline's dependency has been questioned for treating S. maltophilia infections.
嗜麦芽寡养单胞菌由于存在多种固有和获得性耐药机制而难以治疗。复方磺胺甲噁唑是治疗嗜麦芽寡养单胞菌感染的标准治疗方法；左氧氟沙星和米诺环素是首选的潜在替代药物。最近，2024 年，CLSI 降低了米诺环素对嗜麦芽寡养单胞菌的药敏折点。应用修订后的米诺环素药敏折点≤1mg/L，米诺环素的敏感性从 77%（以前的折点，≤4mg/L）显著下降至 35%（修订后的折点，≤1mg/L）。在这一变化之后，米诺环素治疗嗜麦芽寡养单胞菌感染的依赖性受到了质疑。
